Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Hui-yan Luo"'
Autor:
Zi-Jing Li, William Pat Fong, Dong-Sheng Zhang, Hui-Yan Luo, Dong-Liang Chen, Yan-Yu Cai, Zhi-Gang Chen, Jian-Li Duan, Zi-Yao Huang, Yu-Ting Lu, Xiao-Xia Huang, Yu-Hong Li, De-Shen Wang
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-6 (2024)
Abstract Anaplastic lymphoma kinase (ALK) fusion-positive colorectal cancer (CRC) is a rare and chemotherapy-refractory subtype that lacks established and effective treatment strategies. Additionally, the efficacy and safety of ALK inhibitors (ALKi)
Externí odkaz:
https://doaj.org/article/bbdc714779f84f3980277043828d8a35
Publikováno v:
MedComm – Future Medicine, Vol 3, Iss 2, Pp n/a-n/a (2024)
Abstract In the realm of malignant tumor treatment, particularly regarding hematologic malignancies, chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has witnessed remarkable advancements in recent years. This approach involves genetically
Externí odkaz:
https://doaj.org/article/04630aa9869c4be0ba0f49a19c289200
Autor:
De-Shen Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li
Publikováno v:
PLoS Medicine, Vol 21, Iss 5, p e1004389 (2024)
BackgroundIt remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorec
Externí odkaz:
https://doaj.org/article/b9e6a45661f549378ef2d8ab851edf5e
Autor:
Miao-Zhen Qiu, Chaoye Wang, Zhiying Wu, Qi Zhao, Zhibin Zhao, Chun-Yu Huang, Wenwei Wu, Li-Qiong Yang, Zhi-Wei Zhou, Yu Zheng, Hong-Ming Pan, Zexian Liu, Zhao-Lei Zeng, Hui-Yan Luo, Feng Wang, Feng-Hua Wang, Si-Yu Yang, Meng-Xing Huang, Zhexiong Lian, Haiyan Zhang, Rui-Hua Xu
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Epstein‒Barr virus (EBV)-associated gastric cancer (GC) manifests an intriguing immunotherapy response. However, the cellular basis for EBV-imprinted tumour immunity and on-treatment response remains undefined. This study aimed to finely c
Externí odkaz:
https://doaj.org/article/070815274a0c48edad394ffc82fe221e
Autor:
Jia Liu, Wei‐Yi Zhou, Xiao‐Jing Luo, Yan‐Xing Chen, Chau‐Wei Wong, Ze‐Xian Liu, Jia‐ Bo Zheng, Hai‐ Yu Mo, Jun‐Quan Chen, Jia‐Jun Li, Ming Zhong, Yu‐Hong Xu, Qi‐Hua Zhang, Heng‐Ying Pu, Qi‐Nian Wu, Ying Jin, Zi‐Xian Wang, Rui‐Hua Xu, Hui‐Yan Luo
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Background Predictive biomarkers for oesophageal squamous cell carcinoma (ESCC) immunotherapy are lacking, and immunotherapy resistance remains to be addressed. The role of long noncoding RNA (lncRNA) in ESCC immune escape and immunotherapy
Externí odkaz:
https://doaj.org/article/e857b4e2202441d4be456278ca075e04
Autor:
Ming-Yu Lai, Shi-Yang Kang, Yu-Ting Sun, Ting-Ting Quan, Shi-Xun Lu, Cai-Yun He, Zhi-Wei Zhou, Li-Qiong Yang, Hui-Yan Luo, Feng-Hua Wang, Yu-Hong Li, Rui-Hua Xu, Wen-Long Guan, Miao-Zhen Qiu
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background Both Response Evaluation Criteria in Solid Tumors (RECIST) and tumor regression grade (TRG) play key roles in evaluating tumor response. We analyzed the consistency of TRG and RECIST 1.1 for gastric cancer (GC) patients and compar
Externí odkaz:
https://doaj.org/article/a6bf45d872e24b9d9ef7cded62b68d32
Autor:
Miao-Zhen Qiu, Qingjian Chen, Dan-Yang Zheng, Qi Zhao, Qi-Nian Wu, Zhi-Wei Zhou, Li-Qiong Yang, Qiu-Yun Luo, Yu-Ting Sun, Ming-Yu Lai, Sha-Sha Yuan, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Yu-Hong Li, Hui-Zhong Zhang, Rui-Hua Xu
Publikováno v:
Cell Reports, Vol 42, Iss 6, Pp 112576- (2023)
Summary: Gastric mixed adenoneuroendocrine carcinoma (MANEC) is a clinically aggressive and heterogeneous tumor composed of adenocarcinoma (ACA) and neuroendocrine carcinoma (NEC). The genomic properties and evolutionary clonal origins of MANEC remai
Externí odkaz:
https://doaj.org/article/bf5aeca0e50d4f5bb3972a430c761164
Autor:
Jia‐qian Huang, Hui‐yan Luo
Publikováno v:
MedComm – Future Medicine, Vol 2, Iss 1, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/f1cbe8f35a05471e9cd9cf99bd0e66a7
Autor:
Zhen Zhang, Zi-Xian Wang, Yan-Xing Chen, Hao-Xiang Wu, Ling Yin, Qi Zhao, Hui-Yan Luo, Zhao-Lei Zeng, Miao-Zhen Qiu, Rui-Hua Xu
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-18 (2022)
Abstract Background Although immune checkpoint inhibitor (ICI) is regarded as a breakthrough in cancer therapy, only a limited fraction of patients benefit from it. Cancer stemness can be the potential culprit in ICI resistance, but direct clinical e
Externí odkaz:
https://doaj.org/article/5f40daf4e5c248b8b7ed7187b011a379
Autor:
Qi Zhao, Feng Wang, Yan-Xing Chen, Shifu Chen, Yi-Chen Yao, Zhao-Lei Zeng, Teng-Jia Jiang, Ying-Nan Wang, Chen-Yi Wu, Ying Jing, You-Sheng Huang, Jing Zhang, Zi-Xian Wang, Ming-Ming He, Heng-Ying Pu, Zong-Jiong Mai, Qi-Nian Wu, Renwen Long, Xiaoni Zhang, Tanxiao Huang, Mingyan Xu, Miao-Zheng Qiu, Hui-Yan Luo, Yu-Hong Li, Dong-Shen Zhang, Wei-Hua Jia, Gong Chen, Pei-Rong Ding, Li-Ren Li, Zheng-Hai Lu, Zhi-Zhong Pan, Rui-Hua Xu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
The ChangKang (Heathy Bowel) project was established to collect molecular and clinical information of a thousand Chinese colorectal cancer patients. Here, the authors present the genomic landscape of the ChangKang cohort and find a subgroup of patien
Externí odkaz:
https://doaj.org/article/ee0548bf4a574cba8d5b0964a7e38b91